Menschliche T-Zellen reagieren auf CRISPR-assoziierte Nukleasen

Abstract

CRISPR-Cas genome editing enables precise modification of human DNA
in living cells. The technology was adapted from a mechanism by which
bacteria protect themselves from viruses. Previous exposure to these
bacteria can sensitize human immune cells to Cas proteins. Preexisting
antibodies and T cells directed toward Cas antigens warrant a careful
evaluation during clinical application of CRISPR-Cas gene therapy in vivo.
Here, we summarize recent evidence on Cas-directed T cell immunity in
humans and discuss the implications for the clinical translation of the
technology.

Datei